Navigation Links
Study Finds Pre-Hospital Administration Of Bivalirudin Substantially Improves Outcomes Compared To Heparin In Heart Attack Patients
Date:10/30/2013

SAN FRANCISCO, Oct. 30, 2013 /PRNewswire-USNewswire/ -- According to a new study, administering the blood thinner bivalirudin to patients experiencing an ST-elevation myocardial infarction (STEMI, the most serious form of a heart attack) in a pre-hospital setting can reduce the risk of death and major bleeding complications compared to heparin with optional use of glycoprotein IIb/IIIa inhibitors.

Findings from the EUROMAX trial were reported today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. Results of the trial were simultaneously published today in the New England Journal of Medicine.

The EUROMAX trial evaluated the administration of anticoagulant therapy prior to hospital admission by an emergency medical team. The trial compared a heparin-based strategy (with or without glycoprotein IIb/IIIa receptor inhibitors (GPIs) to a bivalirudin-based strategy. The primary endpoint was a composite incidence of death or non-coronary-artery-bypass-graft related protocol major bleeding at 30 days, assessed by intention to treat.

While bivalirudin has been compared to other blood thinners in hospital settings, the EUROMAX study is the first to evaluate these anticoagulant therapy options prior to hospital admission and in conjunction with newer P2Y12 inhibitors such as prasugrel and ticagrelor. The randomized, international, prospective, open-label ambulance trial enrolled 2,198 patients with STEMI and intended for primary PCI, presenting either via ambulance or to centers where PCI is not performed.

Patients either received bivalirudin (n=1,089) or heparin (n=1,109) at guideline-recommended doses (with or without routine or bailout GPI).

After 30 days, patients that received bivalirudin, as compared with the heparin group, experienced a significantly lower rate of death and major bleeding (5.1 percent vs. 8.4 percent, respectively). The secondary composite outcome of death, reinfarction and major bleeding at 30 days was also reduced with bivalirudin (6.7 percent in the bivalirudin group compared to 9.1 percent in the heparin group).  Despite a lower rate of bleeding complications in the bivalirudin-treated patients, the risk of acute stent thrombosis was higher in the bivalirudin group compared to the heparin group (1.1 percent vs. 0.2 percent, respectively), findings that parallel those observed in the HORIZONS-AMI trial.

"The benefits of bivalirudin stemmed from a substantial reduction in major bleeding and were robust and consistent across subgroups, regardless of the adjunctive oral antiplatelet therapy or the arterial access route used for angioplasty," said lead investigator Philippe Gabriel Steg, MD. Dr. Steg is the Director of the Coronary Care Unit at the Hopital Bichat at Assistance Publique - Hopitaux de Paris in France. 

"Findings from EUROMAX provide important additional insights into the role of bivalirudin in the pre-hospital setting prior to primary PCI."

The EUROMAX trial was funded by The Medicines Company. Dr. Steg reported research grant support from New York School of Medicine, Sanofi, and Servier; speaking or consulting for Amarin, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Glaxo-SmithKline, Lilly,  Medtronic, Novartis, Otsuka, Pfizer, Sanofi, Servier, The Medicines Company, and Vivus; and holds stock in Aterovax.

The results of the EUROMAX trial will be presented on Wednesday, October 30 at 9:30 AM PDT in the Main Arena (Moscone South, Esplanade Level, Esplanade Ballroom) of The Moscone Center.

About CRF and TCT
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. CRF is the sponsor of the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Celebrating its 25th anniversary this year, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. For more information, visit www.crf.org and www.tctconference.com.


'/>"/>
SOURCE Cardiovascular Research Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Army Rangers Initiate Groundbreaking Study on Wireless Microcurrent Generating Wound Dressing for Acute Wounds
2. Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
3. Acacia Pharma Initiates Phase II Study With APD403 in Chemotherapy Induced Nausea & Vomiting (CINV)
4. Sharp Edge Labs and SpectraGenetics Sign Agreement to Provide Better Assays for Studying G-Protein Coupled Receptors
5. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
6. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
7. New Study Shows Promise For First Effective Medicine To Treat Cocaine Dependence
8. Philips and RealView Imaging conclude worlds first study to evaluate live 3D holographic imaging in interventional cardiology
9. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
10. Kinex Announces First Patient Dosed in Phase Ib Study of Oraxol, an Orally Dosed Paclitaxel
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):